Determining the prognostic value of identifying genetic mutations in dogs with lymphoma
In human patients diagnosed with diffuse large B-cell lymphoma, evaluation of the MYC gene for genetic alterations is considered a critical component of patient management. MYC gene alterations in people are associated with shorter remission times. Identifying high-risk patients allows these individuals to receive more aggressive therapy earlier in their disease process. In this study, researchers will screen archived samples collected from dogs with diffuse large B-cell lymphoma and determine if MYC gene aberrations correlate with poor prognosis. Findings will help oncologists select the most appropriate and effective treatment to extend the duration and improve quality of life for their canine cancer patients.
Principal Investigator: Matthew Breen, PhD, North Carolina State University
Sponsors: Blue Buffalo Foundation, Petco Foundation, Australian Shepherd Health & Genetics Institute, Inc., Flat-coated Retriever Foundation, Newfoundland Club of America Charitable Trust
Study ID: D16CA-023